Skip to content

MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal

MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00214279
Enrollment
32
Registered
2005-09-21
Start date
2002-05-31
Completion date
2007-11-30
Last updated
2012-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplantation

Brief summary

Part 1 of the study is to gradually withdraw steroids in a group of 50 older renal transplant recipients, converting then from the 3 drug regimen to a 2 drug regimen (cyclosporine and MMF), while carefully monitoring their graft function. 25 subjects would serve as control patients in the study and would remain on the 3 drug regimen (steroids, cyclosporine and MMF). Immunologic status will be determined before and after IS withdrawal using a delayed-type hypersensitivity (DTH) transfer test previously described in the original submission. Both the steroid withdrawal subjects and the control subjects will undergo the DTH testing throughout the 3 years of study participation.

Interventions

DRUGCorticosteroid withdrawal

prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient who have received a kidney transplant during the MMF era * Patients who have stable graft function indicated by a serum creatinine of \< 1.8 mg/dl, or a calculated creatinine clearance of \> 50 ml/minute

Exclusion criteria

* Patients who have had \> 1 rejection episode, * Patients who have had a rejection episode within the past year; * Patients who are steroid dependent due to pre-existing disease (for example, RA or SLE

Design outcomes

Primary

MeasureTime frame
Incidence of Allograft rejection3 years

Secondary

MeasureTime frameDescription
Renal function as determined by serum creatininemeasure after 36 months
Allograft Survival3 years
Immunological function as determined by Trans-vivo delayed hypersensitivity assay (TV-DTH)Day 0 (pre-transplant)Research assay done to determine correlation between the status of donor specific regulation (DSR) and rates of rejection in both arms of the study.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026